Update on pharmacotherapy for pulmonary hypertensionDescription
Pulmonary arterial hypertension (PAH) is a rare disease with a poor prognosis if not treated. Pharmacological treatment options for PAH have increased significantly over the past 10 years, with availability of intravenous, oral and inhaled drugs targeting the nitric oxide, endothelin and prostacyclin pathways.
This module includes an evidence-based overview of PAH treatment as applied to clinical practice, focusing on Group 1 and Group 4 PH (for which there is good evidence for pharmacological treatment).
- Recognise that PAH is a rare disease with poor prognosis if not treated
- Become familiar with several new oral drugs beneficial in treating PAH, impacting future treatments